190 related articles for article (PubMed ID: 31960742)
1. The Role of Angiotensin-Converting Enzyme Inhibitors and β-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients.
Brown SA; Okwuosa TM; Barac A; Volgman AS
J Am Heart Assoc; 2020 Jan; 9(2):e015327. PubMed ID: 31960742
[No Abstract] [Full Text] [Related]
2. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
4. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
Am J Clin Oncol; 2018 Sep; 41(9):909-918. PubMed ID: 28537988
[TBL] [Abstract][Full Text] [Related]
6. Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations.
Abdel-Rahman O; Alorabi M
Expert Rev Anticancer Ther; 2015; 15(7):829-37. PubMed ID: 26013380
[TBL] [Abstract][Full Text] [Related]
7. Heart failure from cancer therapy: can we prevent it?
Totzeck M; Mincu RI; Heusch G; Rassaf T
ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
[TBL] [Abstract][Full Text] [Related]
8. Association of Neurohormonal Antagonists on Incident Cardiotoxicity in Patients With Breast Cancer.
Umadat G; Ray J; Cornell L; Pillai D; Gharacholou SM
Am J Cardiol; 2023 Feb; 188():68-79. PubMed ID: 36473307
[TBL] [Abstract][Full Text] [Related]
9. Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi.
Tsujinaga S; Iwano H; Oshino T; Kadosaka T; Mizuguchi Y; Motoi K; Chiba Y; Koya T; Temma T; Kamiya K; Fukushima A; Koizumi T; Sato T; Takenaka S; Tada A; Ishizaka S; Sarashina M; Omote K; Kamada R; Konishi T; Sato T; Nagai T; Yamashita H; Anzai T
Intern Med; 2020 Sep; 59(17):2155-2160. PubMed ID: 32493855
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity.
Padegimas A; Clasen S; Ky B
Trends Cardiovasc Med; 2020 Jan; 30(1):22-28. PubMed ID: 30745071
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy.
Blaes AH; Gaillard P; Peterson BA; Yee D; Virnig B
Breast Cancer Res Treat; 2010 Jul; 122(2):585-90. PubMed ID: 20058065
[TBL] [Abstract][Full Text] [Related]
12. Cardiac glycoside and beta-adrenergic blocker facilitate resuscitation from bupivacaine cardiotoxicity.
de Jong RH
Anesth Analg; 1994 Feb; 78(2):408-9. PubMed ID: 7906110
[No Abstract] [Full Text] [Related]
13. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
Oliva S; Cioffi G; Frattini S; Simoncini EL; Faggiano P; Boccardi L; Pulignano G; Fioretti AM; Giotta F; Lestuzzi C; Maurea N; Sabatini S; Tarantini L;
Oncologist; 2012; 17(7):917-24. PubMed ID: 22673631
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
15. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
Kalam K; Marwick TH
Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors and beta-blockers in cardiac asymptomatic patients with Duchenne muscular dystrophy.
Fayssoil A
Indian Heart J; 2010; 62(3):273. PubMed ID: 21275309
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
Florido R; Smith KL; Cuomo KK; Russell SD
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939718
[No Abstract] [Full Text] [Related]
18. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.
Geisberg CA; Sawyer DB
Curr Hypertens Rep; 2010 Dec; 12(6):404-10. PubMed ID: 20842465
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
Maradia K; Guglin M
Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
[TBL] [Abstract][Full Text] [Related]
20. Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.
Singh D; Thakur A; Tang WH
Curr Heart Fail Rep; 2015 Jun; 12(3):255-62. PubMed ID: 25869733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
